COLOPHON / THE PUBLISHER
About this BPC-157 research bulletin
A board that pins each BPC-157 finding to its study — and is exact about what it is not.
What Telehealth BPC-157 is
Telehealth BPC-157 is a posted board for the published research on BPC-157, the stable gastric pentadecapeptide. Picture a wall of plates: a sequence, a half-life, an inhibition ratio, a mechanism, a human-data gap — each fact set out on its own and pinned to the study it came from. This is a way of reading the literature, not a service that acts on it. Nothing here is diagnosed, prescribed, or treated, and no consultation is on offer.
The board also has nothing to sell. It stocks no product, dispenses nothing, and takes no order; it summarizes what other people have published, and every number on it traces to a numbered source on the references page. A claim that is not on that reference wall does not go up on the board.
What the name means, and what it does not
The word 'telehealth' on the masthead is a lens, not a service line. It marks the angle this board takes on the record — clinical context and compounded access: who has studied BPC-157, how compounded access is described in general terms, and where the FDA 503A standing currently sits. It does not mean consultations, evaluations, prescriptions, or treatment happen here, because none of that does. There is no staff clinician, no pharmacist, no counter.
No vendor, pharmacy, clinic, or telehealth provider is named on the board, and no dosing or administration is given. Regulation is posted as general information, not medical or legal advice, and not an offer to supply anything. The aim is to make the published record legible and honestly fenced — including its largest limit, that human evidence for BPC-157 is still confined to three small pilot studies.
How we handle the evidence
Established findings and circulating claims are kept on separate rows. Preclinical work is labeled preclinical; the human pilots are labeled small and uncontrolled; popular claims the record does not support — weight loss, muscle building, testosterone increase — are marked unsupported. Where a source could not be confirmed, such as the unverified early-2026 reclassification reports, that is said outright, and the current FDA-citable status is left as the stated fact.
The register stays sober on purpose. The bold plating carries the data; it does not inflate it. A heavy plate and a single accent color make a citation hard to skim past — the opposite of hype.